What is Eternygen?
Founded in June 2012, Eternygen operates as a virtual company, leveraging a robust network of senior industry experts and contract research organizations. The company's core mission revolves around developing novel therapeutic solutions for metabolic diseases, positioning itself at the forefront of biotech innovation. Eternygen's founding team comprises distinguished scientists from leading German academic institutions and experienced entrepreneurs from the venture and industry sectors, bringing a wealth of expertise to its strategic objectives.
How much funding has Eternygen raised?
Eternygen has raised a total of $5.9M across 1 funding round:
Series A
$5.9M
Series A (2020): $5.9M with participation from Epidarex Capital, Evotec SE, and IBB Ventures
Key Investors in Eternygen
Epidarex Capital
Epidarex Capital is a transatlantic venture capital firm that focuses on building breakthrough life science companies in emerging hubs. They act as trusted partners to founders and co-investors, utilizing their deep scientific and industry networks to create exceptional value and shared success.
Evotec SE
Evotec SE is a drug discovery alliance and accelerator company that partners with pharmaceutical and biotechnology companies to accelerate the development of new therapies. Their expertise spans across various therapeutic areas, including metabolic diseases.
IBB Ventures
IBB Ventures is a venture capital fund managed by IBB Beteiligungsgesellschaft mbH, focusing on technology-oriented companies in Berlin. They provide crucial financing for startups and growth-stage companies, particularly in sectors like biotechnology and life sciences.
What's next for Eternygen?
With the recent major strategic investment, Eternygen is poised for accelerated growth and expanded research initiatives. The company's focus on NaCT inhibitors for metabolic diseases aligns with a critical area of unmet medical need, suggesting a strong market potential. This latest backing will likely fuel further development of its pipeline, enhance its R&D capabilities, and potentially support clinical trials. The enterprise-level nature of the funding indicates a strategic phase for Eternygen, aiming to scale its operations and solidify its market position in the competitive biotech landscape.
See full Eternygen company page
